13F Holdings
中文EN

NGNE Neurogene Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1404644 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-40.0%
TTM EPS YoY-22.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-38.4%
ROA-35.8%
ROIC (approx.)-43.7%
Asset turnover—

Leverage & solvency

Liabilities / assets6.1%
Debt / equity0.00x
Current ratio19.97x
Interest coverage-129,924.00x

Cash quality & payout

Operating cash flow / net income0.81x
Accruals ratio-6.8%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$0$925,000$0——
R&D expense$75.01M$60.92M$44.39M$47.51M$39.16M
SG&A expense$28.32M$22.61M$11.19M$9.01M$21.54M
Operating income-$103.33M-$82.61M-$55.58M-$56.52M-$60.70M
Interest expense$5,000$12,000$12,000$2,000—
Pretax income-$90.35M-$75.14M-$36.32M-$55.19M-$60.69M
Income tax$0$0———
Net income-$90.35M-$75.14M-$36.32M-$55.19M-$60.69M
EBITDA-$100.28M-$79.41M-$52.32M-$53.32M-$59.39M
EPS (basic)-4.24-4.28—-1.04-1.10
EPS (diluted)-4.24-4.28—-1.04-1.10
Weighted avg. shares (diluted)21.33M17.57M—55.22M55.04M
Banking
Net interest income———$1.58M$19,000
Balance sheet
Cash & equivalents$103.84M$136.93M$148.72M$82.02M$70.54M
Short-term investments$165.17M$175.82M$48.95M$0$0
Current assets$271.77M$315.92M$200.35M$84.72M$143.99M
PP&E, net$12.79M$15.42M$17.17M$20.11M$6.45M
Intangibles———$0$128,000
Total assets$288.60M$335.73M$222.57M$109.27M$163.26M
Current liabilities$16.41M$15.16M$22.97M$6.65M$8.64M
Total liabilities$23.72M$25.36M$36.55M$10.64M$20.40M
Shareholders' equity$264.89M$310.38M$186.02M-$145.74M-$91.88M
Shares outstanding15.49M14.85M12.82M042.46M
Cash flow statement
Operating cash flow-$77.17M-$70.60M-$51.42M-$52.82M-$47.56M
Capital expenditure$1.18M$808,000$321,000$2.23M$3.26M
Free cash flow-$78.36M-$71.41M-$51.74M-$55.05M-$50.82M
Investing cash flow$14.00M-$125.26M$25.64M-$2.23M-$3.26M
Financing cash flow$30.43M$184.07M$92.48M$66.53M$732,000
Depreciation & amortization$3.04M$3.19M$3.26M$3.20M$1.31M
Stock-based compensation$14.18M$8.32M$1.42M$1.25M$11.56M

Free plan shows the latest 5 periods; Pro shows all 14 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.